- Home
- VERV
VERV
Verve Therapeutics Inc.
as 05-09-2025 4:00pm EST
| Founded: | 2018 | Country: | United States |
| Employees: | N/A | City: | BOSTON |
| Market Cap: | N/A | IPO Year: | 2021 |
| Target Price: | $25.75 | AVG Volume (30 days): | 5.6M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 6 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -2.35 | EPS Growth: | N/A |
| 52 Week Low/High: | $2.87 - $9.31 | Next Earning Date: | 05-20-2025 |
| Revenue: | $32,332,000 | Revenue Growth: | 174.98% |
| Revenue Growth (this year): | -23.81% | Revenue Growth (next year): | -46.54% |
Stock Insider Trading Activity of Verve Therapeutics Inc. (VERV)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Nickerson Joan | VERV | Chief Administrative Officer | Apr 1 '25 | Sell | $4.15 | 2,777 | $11,524.55 | 17,420 | |
| Dorval Allison | VERV | Chief Financial Officer | Apr 1 '25 | Sell | $4.15 | 3,350 | $13,902.50 | 13,280 | |
| Ashe Andrew D. | VERV | See Remarks | Apr 1 '25 | Sell | $4.15 | 2,681 | $11,126.15 | 348,828 | |
| Kathiresan Sekar | VERV | Chief Executive Officer | Apr 1 '25 | Sell | $4.15 | 9,822 | $40,761.30 | 346,686 | |
| Lister Troy | VERV | Chief Scientific Officer | Apr 1 '25 | Sell | $4.15 | 2,189 | $9,084.35 | 6,952 | |
| Politi Jason | VERV | Chief Technical Ops. Off. | Apr 1 '25 | Sell | $4.15 | 3,235 | $13,425.25 | 14,226 |
Latest Verve Therapeutics Inc. News
VERV Breaking Stock News: Dive into VERV Ticker-Specific Updates for Smart Investing
GlobeNewswire
7 days ago
Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
Motley Fool
10 days ago
1 Beaten-Down Stock That Could Skyrocket By 321%, According to Wall Street
Motley Fool
21 days ago
Why Verve Therapeutics Zoomed 40% Higher This Week
Zacks
23 days ago
Biotech Stock Roundup: BMY Down on Study Failure, VERV Up on Study Data & More News
MT Newswires
24 days ago
Verve Therapeutics Shares Jump After Cantor Fitzgerald Upgrade
Motley Fool
24 days ago
Why Verve Therapeutics Is Skyrocketing Today
Zacks
24 days ago
VERV Stock Soars on Superior Efficacy in Phase I Cholesterol Study
MT Newswires
24 days ago
Cantor Fitzgerald Upgrades Verve Therapeutics to Overweight From Neutral
Compare VERV vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "VERV Verve Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.